Адъювантное действие рекомбинантного белка теплового шока (rHSP70) Mycobacterium tuberculosis на иммунный ответ к бактериальным и вирусным антигенам
Диссертация
Однако при использовании стафилококкового антигена на модели генерализованной стафилококковой инфекции при разных схемах и дозах иммунизации не было выявлено преимущества в использовании rHSP70. Более того, на модели локальной стафилококковой инфекции, при использовании различных схем и доз введения препаратов, мы также не получили разницы в степени воспалительной реакции в лапке мышей… Читать ещё >
Содержание
- АДФ аденозиндифосфат
- АКДС вакцина адсорбированная коклюшно-дифтерийно-столбнячная
- АПК антигенпрезентирующая клетка
- АС анатоксин столбнячный очищенный адсорбированный жидкий
- AT антитело
- АТФ аденозинтрифосфорная кислота
- ВИЧ-1 вирус иммунодефицита человека 1 типа
- ВПЧ вирус папилломы человека
- ДА нативный дифтерийный анатоксин д-ДНК денатурированная ДНК ж дендритная клетка
- ДНК дезоксирибонуклеиновая кислота дсРНК двуспиральная рибонуклеиновая кислота ед. единица
- ЕС единица связывания
- ИФА иммуноферментный анализ кДа килодальтон
- KITHib капсульный полисахарид Haemophilus influenzae типа b
- ЛАЛ лизат амебоцитов Limulus polyphemns лпс липополисахарид
- МкАТ моноклональное антитело мкг микрограмм мл миллилитр н-ДНК нативная ДНК нет нитросиний тетразоль
- ОБМ основный белок миелина
- ОДФ ортофенилендиамин
- ОП оптическая плотность пг пикограмм п.о. пара оснований
- ПЦР полимеразная цепная реакция
- ПЭГ полиэтиленгликоль
- РНК рибонуклеиновая кислота
- РПГА реакция пассивной гемагглютинации
- СтАГ стафилококковый антиген
- ТМВ тетраметилбензидина раствор
- ФИ фагоцитарный индекс
- ФСБ фосфатно-солевой буферный раствор
- ФТС фетальная телячья сыворотка
- ЦП цитологический показатель
- Anti-mouse IgG-HRP Anti-mouse immunoglobulin G-horseradish peroxidase -коньюгат пероксидазы хрена и антител против иммуноглобулинов G мыши
- BCG bacillus Calmette-Guerin — противотуберкулезная вакцина на основе М tuberculosis var. bovis
- CD cell differentiation antigens или cluster definition — антиген кластеров дифференцировки клеток
- CpG CpG-мотивы ДНК — cytosine-poly-guanin motif — цитозин-поли-гуанин последовательности
- CTL цитотоксические лимфоциты
- FCA Freund complete adjuvant — полный адъювант Фрейнда
- FITC флуоресцеин изоцианат
- GM-CSF гранулоцитарно-макрофагальный колониестимулирующий фактор gp96 glycoprotein — гликопротеин HSP
- GRPs glucose-regulated proteins — глюкозозависимые белки
- HBsAg поверхностный антиген вируса гепатита В
- I. -IBV hepatitis В virus — вирус гепатита В
- HLA human leukocyte antigen — антиген лейкоцитов человека
- HPV human papilloma virus — папилломавирус человека
- HSP heat shock protein — белок теплового шока
- I. -Ak МНС класса II мыши
- I. FN interferon — интерферон
- I. g immunoglobulin — иммуноглобулин
- I. L interleukine — интерлейкин
- LB Luria-Bertani — питательная среда
- LD летальная доза
- Lf флоккулирующая единица
- Lg логарифм
- MDP muramyl-dipeptide — мурамил дипептид или N-ацетил мурамил-Ь-аланил-Б-изоглютамин мне Major Histocompatibility Complex — главный комплекс гистосовместимости
- MPL monophosphorilyl lipide, А — монофосфорилил липид А
- MyD88 myeloid differentiation primary response gene (88) — цитозольный адаптерный белок
- NF-kB ядерный фактор транскрипции
- NK natural killer — натуральные киллеры
- NKT CD3/NK
- NP нуклеопротеин вируса гриппа
- ODN oligodeoxynucleotides — олигодезоксинуклеотиды
- OmpA outer membrane protein — белок наружной мембраны
- P достоверность разности между опытом и контролем
- PAMP pathogen-associated molecular patterns — патоген-ассоциированные молекулярные структуры
- PRRs pathogen recognition receptors — патогенраспознающие рецепторы
- RAW клеточная линия макрофагов мыши
- SDS sodium dodecyl sulfate — додецилсульфат натрия
- TBE трис-борат-EDTA буферный раствор
- TCR Т cell receptor — рецептор Т-лимфоцитов для антигена
- TGF трансформирующий фактор роста
- Th T-helper — субпопуляция CD4+ Т-лимфоцитов (хелперов)
- TLR Toll-like receptor — Толл-подобный рецептор
- TNF tumor necrosis factor — фактор некроза опухолей
- Trl регуляторные клетки 1-типа
- Treg Т-регуляторный лимфоцит
- V. LP virus-like particles — вирусоподобные частицы
- Z коэффициент выживаемости
- Zn (II) цинк
- АОП разность оптической плотности
Список литературы
- Гланц С. Медико-биологическая статистика. Издательство «Практика». Москва 1999. — 459 с.
- Киселев В. И, Северин Е. С., Пальцев М. А. Противоопухолевые вакцины. Белки теплового шока как индукторы противоопухолевого иммунитета. Молекулярная медицина. 2005. № 1.-С. 3−10.
- Киселев В.И., Дмитриев Г. А., Кубанова A.A. Взаимосвязь вирусных инфекций, передаваемых половым путем, и онкологических заболеваний урогенитального тракта. Вестн. дерматол. — 2000. — № 6. —С. 20—22.
- Медуницын Н.В. Вакцинология. Издательство «Триада-Х». — 1999. -272 с.
- Пастухов Ю.Ф., Екимова И. В. Молекулярные, клеточные и системные механизмы протективной функции белка теплового шока 70 кДа. Молекулярная и клеточная нейробиология. 2005. № 2 — С. 3−25.
- Свешников П.Г., Малайцев В. В., Киселев В. И. Роль белков теплового шока в развитии реакций врожденного иммунитета. Журн. микробиол. 2007. № 5. — С. 96−114.
- Свешников П.Г., Малайцев В. В., Киселев В. И. Функции белков теплового шока в системе адаптивного иммунитета. Конструирование вакцин. Журн. микробиол. 2007. № 6. — С. 108−117.
- Симбирцев A.C. Толл-белки: специфические рецепторы неспецифического иммунитета. Иммунология. 2005. № 6. — С.368−376.
- Хаитов P.M., Игнатьева Г. А., Сидорович И. Г. Иммунология. Москва. «Медицина». — 2000. — 430 с.
- Ястребова Н.Е., Ванеева Н. П., Романова Р. Ю. Антитела к органоспецифическим и органонеспецифическим антигенам в сыворотках крови людей, больных бронхолегочными заболеваниями. Журн. микробиол. 1995. — № 6. — С. 67−68.
- Aguilar J.C., Rodriguez E.G. Vaccine adjuvant revisited. Vaccine. 2007. -Vol.25.-P. 3752−3762.
- Allison A.C., Byars N.E. Immunological adjuvants: desirable properties and side-effects. Mol. Immunol. 1991. Vol.28. — P. 279−84.
- Amato R.J. Vaccine therapy for renal cell carcinoma. Rev.Urol. 2003. -Vol.5. № 2. — P. 65−71.
- Amoid D.S., Faath S., Ramensee H., Schild H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T-lymphocyte upon immunization with the heat-shock protein gp96. J.Exp. Med. 1995. -Vol. 182.-P. 885−889.
- Anthony L.S., Wu H., Sweet H., et al. Priming of CD8+ CTL effector cells in mice by immunization with stress protein-influenza virus nucleoprotein fusion molecule. Vaccine. 1999.-Vol. 17.-N4.-P. 373−383.
- Antonis A.F., Bruschke C.J., Rueda P., et al. A novel recombinant viruslike particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine. 2006. Vol.24. — P. 5481−90.
- Asea A. HSP70 stimulates cytokine production through a CD14-dependent pathway, demonstrating its dual role as a chaperone and cytokine. Nat.Med. 2000. Vol.6. — P. 43542.
- Audibert F.M., Lise L.D. Adjuvants: current status, clinical perspectives and future prospects, Immunol. Today. 1993. Vol.14. — P. 281−284.
- Baker-LePain J.C., Sarzotti M., Nicchitta C.V. Glucose-regulated protein 94/ glycoprotein 96 elicts bystander activation of CD4+ T cell Thl cytokine production in vivo. J. Immunol. 2004. Vol. 172. — P. 4195−4203.
- Banerjee P.P., Vinay D.S., Mathew A., et al. Evidence that glycoprotein 96 (B2), a stress protein, functions as a Th2-specific costimulatory molecule. J. Immunol. 2002. Vol.169. -P. 3507−3518.
- Basu S., Binder R.J., Ramalingam T., et al. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 2001. -Vol.14.-P. 303−313.
- Basu S., Srivastava P.K. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J. Exp. Med. 1999. Vol.189. — P. 797−802.
- Basu S. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partialmaturation signal to dendritic cells and activate the NF-kB pathway. Int. Immunol. 2000. Vol.12. — P. 1539−1546.
- Baudner B.C., Ronconi V., Casini D., et al. MF-59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res. 2009. -Vol.26.-N6.-P. 1477−85.
- Bausinger H. LPS-free heat-shock protein 70 fails to induce APC activation. Eur. J. Immunol. 2002. Vol.32. — P. 3708−3713.
- Becker T., Hartl F.U., Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J.Cell.Biol. 2002. -Vol.158.-P. 1227−1285.
- Bernstein D. I. Sexually transmitted diseases. Vaccines, preven tion and control. New York, 2000.
- Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006. Vol.441. — P. 235−8.
- Beutler B., Jiang Z., Georgel P. et al. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Ann.Rev.Immunol. -2006. Vol.24. — P. 353−389.
- Bogers W.M. A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/fflV infection. AIDS. 2004. Vol.18. -P. 25−36.
- Bogers W.M. CCR5 targeted SIV vaccination strategy preventing or inhibiting SIV infection. Vaccine. 2004. Vol.22. — P. 2974−2984.
- Bohen S.P. Hold.'em and fold’em: chaperones and signal transduction. Science 1995.-Vol.268.-P. 1303−1304.
- Bonato V.L. Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of CD8+ cells, interferon-gamma recovery and reduction of lung injury. Immunology. 2004. Vol.113. -P.130−138.
- Brenner B.G., Wainberg Z. Heat shock proteins: novel therapeutic tools for HIV-infection? Expert. Opin. Biol. Ther. 2001. Vol.1. — № 1. — P. 67−77.
- Bulut Y., Michelsen K.S., Hayrapetian L., et al. Mycobacterium tuberculosis heat shock proteins use diverse Toll-like receptor pathways to activate pro-inflammatory signals. J.Biol.Chem. 2005. Vol.280. — № 22. -P.20 961−20 968.
- Casadevall A. Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle. Infect. Immun.2003.-Vol.71.-P. 4225−4228.
- Casadevall A., Pirofski L.A. Exploiting the redundancy in the immune system: vaccines can mediate protection by eliciting 'unnatural' immunity. J. Exp. Med. 2003. Vol.197. — P. 1401−1404.
- Castelli C., Rivoltini L., Rini F., et al. Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol. Immunother. 2004. Vol. 53. — P. 227−233.
- Chen X. The 170-kDa glucose regulated stress protein is a large HSP70-, HSPllO-like protein of the endoplasmic reticulum. FEBS Lett. 1996. -Vol.380. P. 68−72.
- Chen X. Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity. Immunol. Lett. 2002. Vol.84. — P. 81−87.
- Clarke A.R. Molecular chaperones in protein folding and translocation. Curr. Opin. Struct. Biol. 1996. Vol.6. — P. 43−50.
- Cox E., Verdonck F., Vanrompay D., Goddeeris B. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet. Res. 2006. Vol.37. — P. 511−539.
- Craven R.A. A novel subfamily of HSP70s in the endoplasmic reticulum. Trends Cell Biol. 1997. Vol.7. — 277 p.
- Deenick E.K., Hasbold J., Hodgkin P.D. Decision criteria for resolving isotype switching conflicts by B cells. Eur. J. Immunol. 2005. Vol.35. -P.2949−2955.
- Del Giudice G. Hsp70: a carrier molecule with built-in adjuvancity. Experientia. 1994.-Vol.50.-P. 1061−1066.
- Doody A.D., Kovalchin J.T., Mihalyo M.A., et al. Glycoprotein 96 can chaperone both MHC class I- and II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J. Immunol. 2004. Vol.172. — P. 6087−6092.
- Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002. Voli298. — P. 850−854.
- Dupuis MI, McDonald1 D.M., Ott J. Distribution of adjuvant MF-59 and antigen gD2 after intramuscular injection in mice. Vaccine. 1999. -Vol'. 18i-Pi 434−439.
- Easton DP. The hspllO and Grp 170-stress proteins: newly recognized relatives of the Hsp70s. Cell Stress Chaperones 2000. Vol.5. — P. 276 290}
- Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 1980. Vol.2: — P. 37 083.
- Facciponte J.G. Heat shock proteins and scavenger receptors: role inadaptive immune responses. Immunol. Invest. 2005. — Vol.34. P. 325— 342.
- Faldella G., Alessandroni R., Magini G.M., et al. The preterm infant’s antibody response to a combined"diphtheria, tetanus, acellular pertussis and hepatitis B vaccine. Vaccine. 1998'. Vol.16. — P. 1646−1649.
- Ferraz J.C. A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice. Infect.1.mun. 2004. Vol.72. — P. 6945−6950.
- Freund J., Casals J., Hosmer E.P. Sensitization and antibody formation after injection of tubercle bacili and parafin oil. Proc. Soc. Exp. Biol. Med. 1937.-Vol.37.-P. 509−13.
- Gao B., Tsan M.F. LPS contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. J. Biol. Chem. 2003. -Vol.278.-P. 174−179.
- Gastpar R. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer. Res. 2005. Vol.65. — P. 5238−5247.
- Glenny A.T., Pope C.G., Waddington H., Wallace V. The antigenic value of toxoid precipitated by potassium-alum. J. Path. Bact. 1926. Vol.29. -P. 38−45.
- Glick B. R., Pasternak J. J. Molecular Biotechnology, Principles and Applications of Recombinant DNA. 2nd ed. — ASM Press. — Washington, D.C., 1998.
- Gogas H., Ioannovich J., Dafni U., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J. Med. 2006. Vol.354. — P. 758−60.
- Gor D.O., Mambula S.S. Evaluation of antibody responses elicited by immunization of mice with a pneumococcal antigen genetically fused to murine HSP 70 and murine interleukin-4. Acta Biochim.Biophys.Sin. (Schanghai). 2006. Vol.38. — N.2. — P. 129−135.
- Gullo C.A., Teoh G. Heat shock proteins: to present or not, that is the question. Immunol. Lett. 2004. Vol.94. — P. 1−10.
- Hanson M., Negren P.A., Stahl S. Desgns and production of recombinant subunite vaccines. Biotechnol. Appl. Biochem. 2000. Vol.32. — № 2. -P.95−107.
- Hauet-Broere F., Wieten L., Quichelaar T., et al. Heat shock proteinsinduce T cell regulation of chronic inflamation. Ann.Rheumat.Dis. 2006.65. № 3. — P. 65−68.
- Henderson B., Allan E., Coates A.R.M. Stress wars: the direct role of host and bacterial molecular chaperones inbacterial infection. Infect.Immun. 2006. Vol.74. — № 7. — P. 3693−3706.
- HogenEsch H. Mechanism of stimulation of the immune response by aluminium adjuvants. Vaccine. 2002. Vol.20. — P. 34−39.
- Hong-Tao Li, Jia-Bin Yan, Jing Li, et al. Enhancement of humoral immune responses to HbsAg by heat shock protein gp96 and its N-terminal fragment in mice. World J. Gastroenterol. 2005. Vol.11. — № 19. -P. 2858−2863.
- Houghton A.N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 1994. Vol.180. — P. 1−4.
- Huurman V.A., Decochez K., Mathieu C., et al. Therapy with the hsp 60 peptide DiaPep 277 (trade mark) in C-peptide positive type 1 diabetes patients. Diabetes Metab. Diabetes Metab Res Rev. 2007. № 23. — P. 26 975.
- Insel R.A. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann. NY Acad. Sei. 1995.-Vol.754.-P. 35−47.
- Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004. Vol.5. — P. 987−995.
- Jeannin P., Magistrelli G., Goetsch L., et al. Outer membrane protein A OmpA) a new pathogen-associated presenting cells-impact on vaccine strategies.Vaccine. — 2002. — Vol.4. — P. 23−27.
- Jeurissen A., Billiau A.D., Moens L., et al. CD4+ T lymphocytes expressing CD40 ligand help the IgM antibody respones to soluble pneumococcal polysaccharides via an intermediate cell type. J. Immunol. 2006. Vol.176. — P. 529−536.
- Johnson A.G., Gaines S., Landy M. Studies on the O-antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J. Exp. Med. 1956. Vol. 103. -P. 225−246.
- Kang H.K. Toxoplasma gondii-derived heat shock protein 70 stimulates the maturation of human monocyte-derived dendritic cells. Biochem. Biophys. Res. Commun. 2004. Vol.322. — P. 899−904.
- Kaufmann S.H.E. Novel vaccination strategies. WILEY-VCH Verlag GmbH & Co. KGaA. Weinheim. 2004. 500 p.
- Kelly J.M. Induction of tumor-specific T cell memory by NK cellmediated tumor rejection. Nat. Immunol. 2002. Vol.3. — P. 83−90.
- Kensil C.R. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst. 1996.-Vol.13.-P. 1−55.
- Kita Y. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine. 2005. Vol.23. -P.2132—2135.
- Kobrynski L.J., Sousa A.Q., Nahmias A.J., et al. Cutting edge: antibody production to pneumococcal polysaccharides requires CD1 molecules and CD8+ T cell. J. Immunol. 2005. Vol.174. — P. 1787−1790.
- Korbelik M., Sun J., Cecic I. Photodynamic therapy-induced cell surface expression and release of heat scock proteins: relevance for tumor response. Canc.Res. 2005. Vol.65. — № 3. — P. 1018−1026.
- Kottke T., Sanchez-Perez L., Diaz R.M., et al. Induction of hsp70-mediated Thl7 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer. Res. 2007. Vol.67 — № 24. — P. 11 970−11 979.
- Kovacs-Nolan J., Latimer L., Landi A., et al. The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. Vaccine. 2009. Vol.27. — № 14. — P. 2055−2064.
- Lachmann H.J., Strange ways L., Vyakarmam A., Evans G. Raising antibodies by coupling peptides PPD and immunizing BCG-sensitized animals. Ciba Found. Symp. 1986. — Vol. 119. P. 25−27.
- Lanzavcchia A., Sallusto F. Regulation T cell immunity by dendritic cells. Cell. 2001. Vol.106. — P. 263−266.
- Lee C.J., Lee L.H., Lu C.S., et al. Bacterial polysaccharides as vaccines-immunity and chemical characterization. Adv. Exp. Med. Biol. 2001. -Vol.491.-P. 453−471.
- Lehner T., Wang Y., Whittall T. et al. Functional domains of HSP70 stimulate generation of cytokines and chemokines, maturation of dendritic cells. Biochem. Soc. Trans. 2004. Vol.32. — № 4. — P. 629−632.
- Li J., Ye Z.X., Li K.N., et al. HSP 70 gene fused with Hantavirus S segment DNA significantly enhances the DNA vaccine potency against hantaviral nucleocapsid protein in vivo.Vaccine. 2007. Vol.25. — № 2. -239−252.
- Li Z. Combination of imatinib mesylate with autologous leukocytedeiived heat shock protein and chronic myelogenous leukemia. Clin. Cancer. Res. 2005. Vol.11. — P. 4460−4468.
- Liljequist S., Stahl S. Production of recombinant subunite vaccines: protein immunogens, live delivery systems and nucleic acide vaccines. J. Biotechnol. 1999.-Vol.73.-P. 1−33.
- Lindberg A.A. Polysides (encapsulated bacteria). CR Acad. Sci. III. 1999. -Vol.322.-P. 925−932.
- Lindquist S., Craig E.A. The heat-shock proteins. Annu. Rev. Genet. 1988. -Vol.22.-P. 631−677.
- Lockhart S. Conjugate vaccines. Expert. Rev. Vaccines. 2003. Vol.2. -P. 633−648.
- Long K.H. Identification of heat shock protein 60 as the ligand on Histoplasma capsulatum that mediates binding to CD18 receptors on human macrophages. J. Immunol. 2003. Vol.170. — P. 487−494.
- Lukas, K.V., Lowrie D.B., Stokes R.W., Colston M.J. Tumor cells transfected with a bacterial heat-shock gene lose tumorigenicity and induce protection against tumors. J. Exp. Med. 1993. Vol.178. — P. 343−348.
- Lussow A.R., Barrios C., van Embden J., et al. Mycobacterial heat-shock proteins as carriier molecules. Eur. J. Immunol. — 1991. Vol.21. — № 10. -P. 2297−2302.
- Mangan P., Harrington L., O’Quinn D., et al. Transforming growth factor-p induces development of the TH17 lineage. Nature. 2006. Vol.441. -P.231−4.
- Manjili M.H. Cancer immunotherapy: stress proteins and hyperthermia. Int. J. Hyperthermia 2002. Vol.18. — P. 506−520.
- Manjili M.H. Immunotherapy of cancer using heat shock proteins. Front. Biosci. 2002. Vol.7. — P. 43−52.
- Manjili M. Hi Cancer immunotherapy and heat-shock proteins: promises and challenges. Expert. Opin. Biol. Ther. 2004. Vol. 4. — P. 363−373.
- Massa C. Chaperon and adjuvant activity of hsp70: different’natural killer requirement for cross-priming of chaperoned and bystander antigens. Cancer. Res. 2005. Vol.65. — P. 7942−7949.
- McVernon J., Andrews N., Slack M.P., et al. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet. 2003. Vol.361.-P: 1521−1523.
- Medzhitov R., Janeway C.A. Innate immune recognition: mechanisms and pathways. Immunol. Rev. 2000. Vol.173. — P. 89−97.
- Menoret A., Chandrawarkar R.Y., Srivastava P.K. Natural autoantibodies against heat shock proteins hsp70 and gp96: implication for immunotherapy using heat-shock proteins. Immunology. 2000. Vol.101. -№ 3. — P. 364−370.
- Menoret A. Purification of recombinant and endogenous HSP70s. Methods. 2004. Vol.32. — P. 7−12.
- Michaelsson J. A signal peptide derived from hsp60 binds HLA-E andinterferes with CD94/NKG2A recognition. J. Exp. Med. 2002. Vol.196. -P. 1403−1414.
- Morris G.E., Parker L.C., Ward J.R. et al. Cooperative molecular and cellular networks regulate Toll-like receptor-dependent inflammatory responses. FASEB J. 2006. — Vol.20. — P. 1539−1549.
- Oglesbee M.J. Role for heat shock proteins in the immune response to measles virus infection. Viral Immunol. 2002. Vol.15. — P. 399−416.
- Olafsdottir T.A., Lingnau K., Nagy E., Jonsdottir I. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scand J Immunol. 2009. Vol.69. — № 3 — P. 194−202.
- Osterloh A. Lipopolysaccharide-free heat shock protein 60 activates T cells. J. Biol. Chem. 2004. Vol.279. — P. 47 906−47 911.
- Pardoll D.M. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2002. Vol.2. — P. 227−238.
- PCT, USA, W02005/28 510 Methods, Kits and Compositions for the Developments and Use of Monoclonal Antibodies Specific to Antigens of Low Immunogenecity, 2005.
- Peng M., Chen M., Ling N., et al. Novel vaccines for the treatment of chronic HBV infection based on mycobacterial heat shock protein 70. Vaccine. 2006. Vol.24. — № 7. — P. 887−896.
- Perraut R., Lussow A.R., Gavoille S., et al. Sccessful primate immunization with peptides conjugated- to purified protein derivative or mycobacterial heat shock proteins- in the absence of adjuvants. Clin. Exp. Immunol. 1993. Vol.3. — P. 382−386.
- Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol. Cell. Biol. 2004. Vol.82. — № 5. — P. 488−496.
- Petrovsky N. Novel human polysaccharide adjuvants with dual Thl and Th2 potentiating activity. Vaccine. 2006. Vol.24. — № 2. — P. 26−9.
- Pilla L., Valenti R., Marrari A., et al. Vaccination: role in metastaticmelanoma. Expert Rey Anticancer Ther. 2006. Vol.6. — № 8. — P. 13 051 318.
- Pilla L. Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96. Cancer. Res. 2005. Vol.65. — P. 3942−3949.
- Plotkin S.A., Orenstein W.A., Offit P.A. Vaccines. Fifth edition. 2008. -1748 p.
- Przepiorka D., Srivastava P.K. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol. Med. Today 1998. Vol.4. -P.478—484.
- Queric N., Bennouna S., Alkan S., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8 and 9 to stimulate polyvalent immunity. JEM. 2006. Vol.203. — № 2. — P. 413−424.
- Quintana F .J., Cohen I. R Heat shock proteins as endogenous adjuvants insterile and septic inflammation. J.Immunol. 2005. — Vol.175. P. 27 772 782.
- Ramon G. Precedes pour accroitre la production des antitoxins. Ann. Inst. Pasteur. 1926. Vol.40. — P. 1−10.
- Ramon G. Sur l’augmentation anormale de l’antitoxine chez les chevaux producteurs de serum antidiphterique. Bull. Soc. Centr. Med. Vet. 1925.-Vol.101.-P. 227−234.
- Ramsay M.E., Me Vernon J., Andrews N.J., et al. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J. Infect. Dis. 2003. Vol.188. — P. 481−485.
- Rockley A.G., Shepherd J. Corton J.V. Detection of heat shock protein 70 (Hsp70) and1 anti-Hsp70 antibodies in serum of normal individuals. Immunol. Invest. 1998. Vol.27. — № 6. — P. 367−377.
- Scheckelhoff M., Deeper G.S. The: protective immune: response to heat shock protein 60 of Histoplasma capsulatum is mediated by a subset of V beta 8.1/8.2+ T cells. Ji Immunol. 2002. -Vol: 169- -P: 5818−5826:
- Srivastava P.K. Therapeutic cancer vaccines. 2006. Vol.18. — N.2. -P.201−205.
- Srivastava P.K., Menoret A., Basu S., et al. Heat shock proteins come of age: primitive functions acquire new roles in adaptive world. Immunity. 1998.-Vol.8.-P. 657−665.
- Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. 2002. Vol.2. — P. 185−194.
- Stebbing J., Gazzard B., Portsmouth S., et al. Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor. Blood. 2003. Vol.102. — № 5. — P. 1806−1814.
- Stebbing J., Savage P., Patterson S., et al. All for CD91 and CD91 for all. J.Antimicrob.Chemother. 2004. Vol.53. — P. 1−3.
- Strbo N. Perforin is required for innate and adaptive immunity induced by heat shock protein gp96. Immunity. 2003. Vol.18. — P. 381−390.
- Stuart-Harris C.H. Adjuvant influenza vaccines. Bull. WHO. 1969. -Vol.41.-P. 617−621.
- Takeda K., Akira S. Toll-like receptors in innate immunity. Int. Immunol. 2005.-Vol.17.-P. 1−14.
- Tamura Y. Immunotherapy of tumor with autologous tumor-derived heat shock protein preparations. Science. 1997. Vol.278. — P. 117−120.
- Theriault J.R., Adachi H., Calderwood S.K. Role of scavenger receptors in the bindingand internalization of heat shock protein 70. J.Immunol. 2006. -Vol.177. -№ 12.-P. 8604−8611.
- Theriault J.R., Mambula S.S., Sawamura T., et al. Extracellular HSP70 binding to surface receptors present on antigen presenting cells and endothelial/epithelial cells. FEBS Lett. 2005. Vol.579. -№ 9. — P. 19 511 960.
- Todryk S.M., et al. Heat shock proteins refine the danger theory. Immunology. 2000. -Vol.99. P. 334−337.
- Tong N.K., Beran L., Kee S.A., et al. Immunogenicil Y and safely of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney. Int. 2005. Vol.68. — P. 2298−303.
- Tsan M.-F., Gao B. Endogenous ligands of Toll-like receptors. J. Leucocyte Biol. 2004. Vol.76. — P. 514−519.
- Tsan M-F., Gao*B. Heat shock protein and innate immunity. Cellular and Molecular Immunology. 2004. Vol. 1. -№ 4. — P. 274−279:
- Udono H., Srivastava P.K. Comparison of tumor-specificimmunogenicities of stress-induced proteins gp96, hsp90 and hsp70. J. Immunol. 1994. -Vol.152.-P. 5398−5403.
- Ullrich S.J. A mouse tumor-specific transplantation antigen is a heatshock related protein. Proc. Natl. Acad. Sci. U.S.A. 1986. Vol.83. — P. 3121— 3125.
- Vabulas R.M. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J. Biol. Chem. 2002. Vol.277. — P. 1 510 715 112.
- Valiante N.M., O’Hagan D.T., Ulmer J.B. Innate immunity and biodefence. Cellular Microbiology. 2003. Vol.5. — № 11. — p. 755−760.
- Vanags D., Williams B., Johnson B., et al. Therapeutic efficacy and safetyof chaperonin 10 in patients with" rheumatoid arthritis: a double-blind randomised trial- Lancet. 2006. Vol.368. — № 9538. — P. 55−63.
- Veldhoen M., Hocking R., Atkins C., et al. TGEB- in the context of an inflammatory cytokine milieu supports de novo differentiaton ofTL-n-producing T cells. Immunity. 2006. VoL24. — PI 179−189.
- Vogel F.R. Modulation of the immune response to vaccine- antigens. Dev. Biol. Stand. Basel. Karger. 1998. Vol 92. — P. 241−148.
- Wan T.,. Zhou- X., Chen' G., et al. Novel heat' shock protein. Hsp70Ll activates dendritic cells as-Thl polarizing adjuvant. Immunobiology. 2004. -Vol.103-P. 1747−1754.
- Weintraub' A. Immunology of bacterial polysaccharide antigens. Carbohydr. Res. 2003. Vol.338. — P. 2539−2547.
- Young R. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J. Immunol. 1996. Vol.156.1. P.873−879.
- Young S.L., Wilson M., Wilson S., et al. Transcutaneous vaccination with virus-like panicles. Vaccine. 2006. Vol.24. — P. 5406−5412.
- Zugel U., Kaufmann S.H.E. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin.Microbiol.Rev. 1999. -Vol.12. — № 1. — P. 19−39.
- Zugel, U., Kaufmann S.H.E. Immune response against heat shock proteins in infectious diseases. Immunobiology. 1999. Vol.201. — P. 22−35.